Today (10.11.14) the Scottish Medicines Consortium (SMC) has published it’s latest round of guidance which includes it’s first guidance for Daclatasvir. This decision gives Scottish Health Boards an assurance that the drug offers value for money and gives them permission to use it in a restricted way.
Daclatasvir is a new drug intended to be used in combination (with Sofosbuvir) to provide clinicians with a interferon free combination therapy for Hepatitis C. Scottish Health Boards receive no additional funding as the result of new advice from the SMC and still have to develop policy for how new drugs will be used.
Haemophilia Scotland had made a submission to the SMC in favour of approval for Daclatasvir from SMC, primarily on the grounds of improved patient and clinical choice and the importance of moving away from interferon as a therapy.
You can find our more about the SMC decision and what restrictions have been applied on the SMC website.